Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Deutsches Rheuma-Forschungszentrum Berlin currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, GRASER, JENNIFER E, who is responsible for 1 busiest examiner pending office action. The lack of distribution across multiple examiners indicates that the current patent strategy is focused on 1 active application. This concentration allows the legal team to focus their technical arguments on the specific standards of 1 distinct art unit.
Because the portfolio involves only 1 distinct art unit, the practitioner can prioritize the specific examination trends and preferences of that unit. This simplifies the administrative burden of tracking different examiner behaviors. The presence of 1 pending office action indicates a streamlined engagement with the patent office, requiring a targeted response to the 1 distinct examiner involved. By addressing the 1 busiest examiner pending office action, the applicant can focus on the specific requirements of the pending application currently in the queue.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRASER, JENNIFER E | 1 | 76.7% | +23.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265081 | IMMUNOGENIC COMPOSITIONS FOR PRODUCING NEUTRALISING ANTIBODIES AGAINST SARS-COV | GRASER, JENNIFER E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265081 | IMMUNOGENIC COMPOSITIONS FOR PRODUCING NEUTRALISING ANTIBODIES AGAINST SARS-COV | GRASER, JENNIFER E | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18265081 | IMMUNOGENIC COMPOSITIONS FOR PRODUCING NEUTRALISING ANTIBODIES AGAINST SARS-COV | GRASER, JENNIFER E | 1645 | §103§112 | Non-Final OA | — | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial